Abstract
Vinblastine and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) were evaluated in a murine renal cell carcinoma model. Both drugs significantly decreased tumor weight and the percentage of distant metastases and very significantly prolonged the survival of tumor-bearing animals. Both also exhibited a dose-related effect. The therapeutic index of vinblastine was limited by signs of systemic toxicity, while the dosage of CCNU might have been limited by its tendency to suppress host immune response to tumor, based on observations of this renal tumor model. Vinblastine may prove clinically useful in early or prophylactic treatment of resected renal tumors, whereas CCNU may be very useful in prolonging survival of patients with renal tumors which have already metastasized. Therefore, both drugs, either alone or combined, may have clinical value in the treatment of metastatic renal carcinoma. Vinblastine may serve best as initial postsurgical treatment, with the addition of CCNU if metastatic disease is documented or progressive. The 3 response criteria evaluated by this model were tumor growth, tumor spread, and prolongation of survival. These seemed most clinically relevant and this model appeared to resemble closely the clinical situation of disseminated renal cell carcinoma in man.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
